Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

GILD

Gilead Sciences, Inc.

Jul 26 • 04:00PM ET

77.01

Dollar change +0.50
Percentage change 0.65	%

Healthcare • Drug Manufacturers - General • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VOO QQQ SPY IVV XLV VTV IBB COWZ MOAT

Scroll to Statements

Index	NDX, S&P 500	P/E	214.69	EPS (ttm)	0.36	Insider Own	0.09%	Shs Outstand	1.25B	Perf Week	6.13%
Market Cap	95.94B	Forward P/E	10.72	EPS next Y	7.18	Insider Trans	-1.25%	Shs Float	1.24B	Perf Month	11.11%
Income	484.00M	PEG	39.87	EPS next Q	1.60	Inst Own	85.44%	Short Float	1.71%	Perf Quarter	17.99%
Sales	27.42B	P/S	3.50	EPS this Y	-44.26%	Inst Trans	0.85%	Short Ratio	2.82	Perf Half Y	-4.01%
Book/sh	14.08	P/B	5.47	EPS next Y	91.71%	ROA	0.82%	Short Interest	21.25M	Perf Year	-0.23%
Cash/sh	4.86	P/C	15.83	EPS next 5Y	5.38%	ROE	2.51%	52W Range	62.07 - 87.86	Perf YTD	-4.94%
Dividend Est.	3.10 (4.03%)	P/FCF	12.15	EPS past 5Y	1.55%	ROI	1.24%	52W High	-12.35%	Beta	0.18
Dividend TTM	3.04 (3.95%)	Quick Ratio	0.94	Sales past 5Y	4.16%	Gross Margin	77.68%	52W Low	24.07%	ATR (14)	1.90
Dividend Ex-Date	Jun 14, 2024	Current Ratio	1.08	EPS Y/Y TTM	-91.37%	Oper. Margin	34.04%	RSI (14)	73.90	Volatility	2.87% 2.26%
Employees	18000	Debt/Eq	1.44	Sales Y/Y TTM	2.13%	Profit Margin	1.77%	Recom	2.19	Target Price	82.65
Option/Short	Yes / Yes	LT Debt/Eq	1.23	EPS Q/Q	-517.48%	Payout	66.62%	Rel Volume	0.99	Prev Close	76.51
Sales Surprise	5.17%	EPS Surprise	11.60%	Sales Q/Q	5.66%	Earnings	Aug 08 AMC	Avg Volume	7.53M	Price	77.01
SMA20	9.45%	SMA50	13.67%	SMA200	4.81%	Trades		Volume	7,452,346	Change	0.65%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-08-24	Upgrade	Raymond James	Mkt Perform → Outperform	$93
May-01-24	Reiterated	Maxim Group	Buy	$90 → $85
Apr-24-24	Upgrade	HSBC Securities	Reduce → Hold	$69
Feb-22-24	Downgrade	Truist	Buy → Hold	$91 → $82
Nov-09-23	Initiated	Deutsche Bank	Hold	$75
Sep-08-23	Upgrade	BofA Securities	Neutral → Buy	$88 → $95
Sep-06-23	Initiated	HSBC Securities	Reduce	$71
Jul-24-23	Reiterated	Barclays	Equal Weight	$81 → $80
May-16-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$90 → $100
Apr-28-23	Resumed	Piper Sandler	Overweight	$105
Jan-03-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$87
Dec-13-22	Resumed	BofA Securities	Neutral	$85
Dec-09-22	Downgrade	DZ Bank	Buy → Hold	$90
Oct-31-22	Upgrade	Barclays	Underweight → Equal Weight	$60 → $76
Oct-28-22	Upgrade	Truist	Hold → Buy	$76 → $91
Oct-28-22	Upgrade	Piper Sandler	Neutral → Overweight	$79 → $96
Oct-28-22	Reiterated	Wells Fargo	Equal Weight	$74 → $75
Oct-28-22	Reiterated	RBC Capital Mkts	Outperform	$79 → $82
Oct-28-22	Reiterated	JP Morgan	Overweight	$80 → $87
Oct-28-22	Reiterated	Jefferies	Buy	$78 → $86

Show Previous Ratings

Jul-25-24 04:05PM	Gilead Sciences to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024 (Business Wire)
09:15AM	Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline (Business Wire)
06:15AM	3 Stocks That Can Help You to Get Richer in 2024 and Beyond (Motley Fool)
Jul-24-24 04:30AM	Full Efficacy and Safety Results for Gilead Investigational Twice-Yearly Lenacapavir for HIV Prevention Presented at AIDS 2024 (Business Wire)
Jul-23-24 01:00PM	Invest $50K in CVS Health and Gilead Sciences to Become a Dividend Millionaire (Benzinga)
06:32AM	Loading…
06:32AM	ViiV Healthcares Dovato as effective as Biktarvy in Phase IV HIV trial (Clinical Trials Arena)
03:52AM	Nanotechnology in medicine: Who are the leading public companies? (Medical Device Network)
Jul-22-24 06:00PM	Gilead Sciences (GILD) Stock Declines While Market Improves: Some Information for Investors (Zacks)
01:54PM	UNAIDS boss calls on Gilead to provide miracle drug to developing countries (Pharmaceutical Technology)
04:00AM	Gilead and the Elton John AIDS Foundation Announce Additional Five Years of RADIAN Partnership to Help Address the Growing HIV Crisis in Eastern Europe and Central Asia (Business Wire)
Jul-18-24 05:45PM	T-Mobile US, Inc. (TMUS): Why Are Hedge Funds Bullish on This Communication and Media Stock Right Now? (Insider Monkey)
09:00AM	Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Jul-17-24 08:50AM	Chief Medical Officer Merdad Parsey to Leave Gilead Early 2025 (Business Wire)
07:15AM	Want $3,000 In Passive Income? Invest $51,000 in These 3 High-Yield Dividend Plays (Motley Fool)
05:52AM	Gilead set to unveil data from HIV/AIDS trials (Clinical Trials Arena)
06:00PM	Loading…
Jul-16-24 06:00PM	Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know (Zacks)
08:30AM	Gilead to Highlight Landmark Progress in Research Across HIV Prevention, Treatment and Cure Programs at AIDS 2024 (Business Wire)
Jul-15-24 07:34PM	Analyst Report: Gilead Sciences, Inc. (Morningstar Research)
10:51AM	The 3 Most Undervalued Nasdaq 100 Stocks to Buy in July 2024 (InvestorPlace)
Jul-14-24 06:30AM	3 Dividend Growth Stocks to Buy and Hold (Motley Fool)
Jul-13-24 11:00AM	The 7 Most Undervalued Healthcare Stocks to Buy in July 2024 (InvestorPlace)
Jul-11-24 10:30AM	3 Underappreciated Stocks About to Break Their Chains (InvestorPlace)
Jul-10-24 06:00PM	Why Gilead Sciences (GILD) Outpaced the Stock Market Today (Zacks)
Jul-09-24 06:00AM	7 Cheap Biotech Stocks With Major Upside Potential (InvestorPlace)
Jul-08-24 12:03PM	Gilead Gets Analyst Upgrade on 'Outstanding' HIV Treatment Data (Investopedia)
09:08AM	Gilead (GILD) Loses 17.6% YTD: How Should You Play the Stock? (Zacks)
Jul-04-24 02:13PM	FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals (InvestorPlace)
10:01AM	3 Undervalued Biotech Gems With 200%+ Analyst Price Targets (InvestorPlace)
Jul-03-24 06:00AM	5 FDA decisions to watch in the third quarter (BioPharma Dive)
Jul-02-24 03:17AM	Insider Sale: Chief Medical Officer Merdad Parsey Sells Shares of Gilead Sciences Inc (GILD) (GuruFocus.com)
08:45AM	Loading…
Jul-01-24 08:45AM	Gilead Benefit Helps Employees Navigate Cancer Care (ACCESSWIRE)
06:55AM	Should You Hold Gilead Sciences (GILD)? (Insider Monkey)
06:50AM	3 Magnificent Stocks Retirees Can Buy and Hold Forever (Motley Fool)
Jun-27-24 03:28PM	American Cancer Society Projects Over 2 Million New Cases in 2024: Biotech Innovations Respond (PR Newswire)
Jun-25-24 06:00PM	Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know (Zacks)
Jun-23-24 01:38PM	7 Dividend Stocks to Buy Now: June 2024 (InvestorPlace)
Jun-21-24 03:43PM	Why A Broken Wing Butterfly Might Make Money In Gilead Sciences Stock (Investor's Business Daily)
03:43PM	GILD Stock Today: Why A Broken Wing Butterfly Might Make Money In Gilead Sciences Stock (Investor's Business Daily)
12:58PM	US indexes open mixed, pharmaceutical stocks climb: Morning Brief (Yahoo Finance Video)
09:41AM	Gilead sees encouraging results from shot to prevent HIV (Yahoo Finance Video)
09:17AM	Gilead (GILD) Up as Twice-Yearly HIV Shot Prevents Infection (Zacks)
09:14AM	Nvidia, triple-witching, biotech stock gains: 3 Things (Yahoo Finance Video)
08:45AM	Defying the Norms: 3 High P/E Stocks With Room to Run (InvestorPlace)
07:34AM	5 Things to Know Before the Stock Market Opens (Investopedia)
07:10AM	Nvidia loses spot as most valuable US company, triple-witching pressures market: Yahoo Finance (Yahoo Finance Video)
06:31AM	Strength Seen in Gilead (GILD): Can Its 8.5% Jump Turn into More Strength? (Zacks)
03:39AM	CarMax, Gilead and Sarepta rise premarket; Nvidia falls (Investing.com)
Jun-20-24 05:35PM	Housing trends, HPE CEO on Nvidia partnership: Market Domination (Yahoo Finance Video) +8.46%
05:06PM	S&P 500 Gains and Losses Today: Index Dips After Briefly Crossing 5,500 (Investopedia)
04:21PM	Gileads Twice-Yearly Shot Prevents HIV. Where the Stock Is Headed. (Barrons.com)
04:16PM	Why Wall Street Is Chasing Ozempic Wannabes (The Wall Street Journal)
04:09PM	Gilead Sciences stock jumps on HIV treatment trial success (Yahoo Finance Video)
04:06PM	Gilead Flashes A Bullish Sign After HIV Drug Proves 100% Effective (Investor's Business Daily)
03:14PM	Gilead Stock Surges on Strong Results in HIV Drug Study (Investopedia)
02:49PM	Gilead Stock Gets Boost From HIV Drug Study Results (The Wall Street Journal)
12:40PM	Gilead's Twice-Yearly Shot Prevents HIV (Barrons.com)
12:24PM	Gilead Stock Jumps. Its Twice-Yearly Shot Prevents HIV. (Barrons.com)
12:12PM	Gilead Shot Prevents All HIV Cases in Trial of African Women (Bloomberg)
09:00AM	Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
08:51AM	Gileads Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada for HIV Prevention (Business Wire)
08:45AM	Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033 (GlobeNewswire)
07:30AM	Twice-yearly shots of Gilead HIV drug effective in large prevention study (BioPharma Dive)
Jun-19-24 09:15AM	Gilead and Kite Pharma Celebrates Pride Month (ACCESSWIRE)
Jun-17-24 04:02PM	Gilead Has A Narrative-Changing Revelation For Its Weight-Loss Contender (Investor's Business Daily)
03:27PM	7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline (InvestorPlace)
Jun-14-24 04:19PM	Gilead Sciences Jumps After Its Weight-Loss Drug Emerges From Under The Radar (Investor's Business Daily)
02:27PM	Gilead Stock Gains. Its Trying to Get Into the Obesity Drug Game. (Barrons.com)
07:01AM	Gilead Sciences Inc's Dividend Analysis (GuruFocus.com)
03:00AM	New Kite Clinical Research and Real-World Evidence for Yescarta Demonstrate Benefit From Earlier Lines of Treatment (Business Wire)
Jun-13-24 06:00PM	Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts (Zacks)
Jun-12-24 09:00AM	How Luciana Preger Is Helping Advance Gilead's Work in Oncology (ACCESSWIRE)
Jun-08-24 06:50AM	3 Stocks With Mouthwatering Dividends You Can Buy Right Now (Motley Fool)
Jun-07-24 05:50PM	Gilead Sciences (GILD) Gains As Market Dips: What You Should Know (Zacks)
11:36AM	The City With the highest HIV/AIDS Rates in the US (Insider Monkey)
11:35AM	20 Cities With the Highest HIV/AIDS Rates in the US (Insider Monkey)
Jun-06-24 09:00AM	Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know (Zacks)
04:45AM	Gileads seladelpar shows promise in primary biliary cholangitis trial (Clinical Trials Arena)
04:30AM	Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA (Business Wire)
Jun-05-24 09:45AM	Should You Buy the 3 Highest-Yielding Dividend Stocks in the Nasdaq-100? (Motley Fool)
09:15AM	Gilead Sciences: Preserving Fertility in the Face of a Cancer Diagnosis (ACCESSWIRE)
07:55AM	Lilly details MASH data for tirzepatide; Cytokinetics comments on past sale talks (BioPharma Dive)
07:00AM	The Dividend Dynamos: 7 Stocks That Will Energize Your Income Stream (InvestorPlace)
06:40AM	7 Dividend Stocks to Invest In for a Lifetime of Income (InvestorPlace)
05:06AM	Gilead progresses subject enrolment in HIV prevention trials (Clinical Trials Arena)
04:25AM	J&J seeks expanded approvals for paediatric HIV-1 therapy (Pharmaceutical Technology)
02:00AM	Gileads Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis (Business Wire)
Jun-04-24 03:57PM	National Institutes of Health Kickstarts Gilead Sponsored Trials For Twice-Yearly HIV Prevention Injection (Benzinga)
06:15AM	3 Dividend Stocks That Even Ken Griffin Is Buying (InvestorPlace)
Jun-03-24 04:26PM	Hedge Funds are Bullish on This Gene Therapy Stock (Insider Monkey)
04:17PM	9 Best Gene Therapy Stocks to Buy Now (Insider Monkey)
01:59PM	Gilead (GILD), RCUS Announce Data From Colorectal Cancer Study (Zacks)
10:00AM	Kites Tecartus Demonstrates Sustained Overall Survival in Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (Business Wire)
09:00AM	Encouraging New Data Presented on Kites Yescarta for Relapsed/Refractory Central Nervous System Lymphoma (Business Wire)
Jun-02-24 08:00AM	Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer (Business Wire)
Jun-01-24 08:00AM	Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers (Business Wire)
May-31-24 01:01PM	Gilead's (GILD) Urothelial Cancer Study Did Not Meet Its Primary Goal (Zacks)
12:18PM	15 Most Profitable Biotechnology Companies in the World (Insider Monkey)
08:07AM	EVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024 (Business Wire)
07:01AM	Gileads Trodelvy misses goal in bladder cancer study (BioPharma Dive)
04:25AM	Gileads Phase III urothelial cancer trial fails to meet primary endpoint (Clinical Trials Arena)

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Parsey Merdad	Chief Medical Officer	Jul 01 '24	Sale	68.63	2,000	137,260	96,380	Jul 01 08:06 PM
GILEAD SCIENCES, INC.	10% Owner	Apr 02 '24	Buy	0.76	485,250	368,790	7,345,473	Apr 03 06:50 PM
Parsey Merdad	Chief Medical Officer	Apr 01 '24	Sale	72.96	2,000	145,920	96,304	Apr 02 06:38 PM
Parsey Merdad	Chief Medical Officer	Feb 29 '24	Sale	72.74	8,230	598,624	92,706	Feb 29 06:35 PM
Parsey Merdad	Chief Medical Officer	Feb 28 '24	Sale	73.18	2,000	146,360	100,936	Feb 29 06:35 PM
GILEAD SCIENCES, INC.	10% Owner	Feb 12 '24	Buy	22.00	910,000	20,020,000	4,126,119	Feb 13 05:48 PM
GILEAD SCIENCES, INC.	10% Owner	Jan 29 '24	Buy	21.00	15,238,095	319,999,995	30,061,124	Jan 31 05:00 PM
Dickinson Andrew D	Chief Financial Officer	Jan 16 '24	Sale	85.78	5,000	428,900	101,534	Jan 17 06:01 PM
Mercier Johanna	Chief Commercial Officer	Jan 09 '24	Sale	85.23	8,242	702,466	82,729	Jan 10 03:58 PM
Dickinson Andrew D	Chief Financial Officer	Oct 17 '23	Sale	80.00	5,000	400,017	104,003	Oct 18 04:31 PM
Parsey Merdad	Chief Medical Officer	Sep 12 '23	Sale	76.99	1,501	115,562	70,130	Sep 13 06:50 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GILD

Gilead Sciences, Inc.

Upgrade your FINVIZ experience